Calamos Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$45M Sell
356,488
-56,102
-14% -$7.39M 0.15% 144
2026
Q1
$57.5M Buy
412,590
+187,021
+83% +$26.2M 0.2% 110
2025
Q4
$27.7M Sell
225,569
-9,121
-4% -$1.11M 0.1% 209
2025
Q3
$26.1M Sell
234,690
-95
-0% -$10.8K 0.1% 228
2025
Q2
$26M Hold
234,785
0.1% 235
2025
Q1
$26.3M Buy
234,785
+2,514
+1% +$259K 0.11% 207
2024
Q4
$21.5M Hold
232,271
0.09% 244
2024
Q3
$19.5M Sell
232,271
-5,671
-2% -$433K 0.08% 272
2024
Q2
$16.3M Sell
237,942
-8,703
-4% -$581K 0.07% 288
2024
Q1
$18.1M Sell
246,645
-6,173
-2% -$475K 0.09% 269
2023
Q4
$20.5M Sell
252,818
-4,767
-2% -$371K 0.1% 246
2023
Q3
$19.3M Sell
257,585
-152,623
-37% -$11.7M 0.1% 247
2023
Q2
$31.6M Buy
410,208
+113
+0% +$9.01K 0.16% 171
2023
Q1
$34M Sell
410,095
-31,768
-7% -$2.63M 0.17% 151
2022
Q4
$37.9M Buy
441,863
+52,186
+13% +$4.13M 0.18% 152
2022
Q3
$24M Buy
389,677
+380
+0.1% +$24K 0.11% 220
2022
Q2
$24.1M Buy
389,297
+9,512
+3% +$589K 0.1% 231
2022
Q1
$22.6M Buy
379,785
+44,833
+13% +$2.87M 0.08% 260
2021
Q4
$24.3M Buy
334,952
+11,018
+3% +$759K 0.09% 237
2021
Q3
$22.6M Buy
323,934
+25,507
+9% +$1.79M 0.1% 229
2021
Q2
$20.6M Buy
298,427
+56,738
+23% +$3.79M 0.09% 246
2021
Q1
$15.6M Buy
241,689
+5,955
+3% +$384K 0.09% 251
2020
Q4
$13.7M Sell
235,734
-8,088
-3% -$488K 0.08% 268
2020
Q3
$15.4M Sell
243,822
-182,099
-43% -$12.6M 0.1% 224
2020
Q2
$32.8M Sell
425,921
-116,560
-21% -$8.93M 0.23% 119
2020
Q1
$40.6M Buy
542,481
+4,885
+0.9% +$338K 0.32% 86
2019
Q4
$34.9M Sell
537,596
-4,346
-0.8% -$283K 0.17% 161
2019
Q3
$34.3M Buy
541,942
+23,419
+5% +$1.53M 0.19% 163
2019
Q2
$35M Sell
518,523
-44,661
-8% -$2.94M 0.19% 157
2019
Q1
$36.6M Buy
563,184
+2,912
+0.5% +$194K 0.23% 139
2018
Q4
$35M Buy
560,272
+33,331
+6% +$2.33M 0.23% 119
2018
Q3
$40.7M Buy
526,941
+187,717
+55% +$14.2M 0.22% 119
2018
Q2
$24M Buy
339,224
+18,191
+6% +$1.28M 0.15% 193
2018
Q1
$24.2M Buy
321,033
+5,186
+2% +$412K 0.16% 185
2017
Q4
$22.6M Sell
315,847
-2,987
-0.9% -$227K 0.12% 179
2017
Q3
$25.8M Buy
318,834
+10,098
+3% +$772K 0.2% 159
2017
Q2
$21.9M Sell
308,736
-249,599
-45% -$16.6M 0.16% 183
2017
Q1
$37.9M Sell
558,335
-102,104
-15% -$7.18M 0.3% 95
2016
Q4
$47.3M Sell
660,439
-6,137
-0.9% -$456K 0.38% 68
2016
Q3
$52.7M Sell
666,576
-56,758
-8% -$4.61M 0.38% 78
2016
Q2
$60.3M Buy
723,334
+177,612
+33% +$15.8M 0.42% 64
2016
Q1
$50.1M Buy
545,722
+13,902
+3% +$1.25M 0.33% 91
2015
Q4
$53.8M Sell
531,820
-20,569
-4% -$2.14M 0.34% 90
2015
Q3
$54.2M Buy
552,389
+267
+0% +$29.7K 0.37% 78
2015
Q2
$64.6M Buy
552,122
+155,797
+39% +$17M 0.4% 69
2015
Q1
$38.9M Sell
396,325
-325,787
-45% -$33.1M 0.24% 127
2014
Q4
$68.1M Sell
722,112
-210,592
-23% -$21.8M 0.45% 64
2014
Q3
$99.3M Sell
932,704
-754,827
-45% -$73.9M 0.66% 37
2014
Q2
$140M Sell
1,687,531
-304,119
-15% -$23.7M 0.89% 25
2014
Q1
$141M Sell
1,991,650
-45,845
-2% -$3.6M 0.9% 25
2013
Q4
$153M Sell
2,037,495
-261,714
-11% -$18.2M 0.97% 23
2013
Q3
$144M Sell
2,299,209
-1,452,155
-39% -$86.8M 0.91% 28
2013
Q2
$192M Buy
+3,751,364
New +$196M 1.26% 18

Other funds holding GILD

Calamos Advisors's GILD Position: Q2 2026 in Review

Calamos Advisors reduced its Gilead Sciences (GILD) stake by 14% in Q2 2026, selling an estimated $7.39M and leaving 356,488 shares worth $45M. The position accounts for 0.15% of the portfolio, ranked #144.

Calamos Advisors first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $192M in Q2 2013. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Calamos Advisors held 356,488 shares of Gilead Sciences worth $45M as of Q2 2026.
  • Calamos Advisors sold 56,102 Gilead Sciences shares in Q2 2026, an estimated $7.39M.
  • Gilead Sciences made up 0.15% of Calamos Advisors's portfolio in Q2 2026, its #144 holding.
  • Calamos Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Calamos Advisors's Gilead Sciences position peaked at $192M in Q2 2013.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.